Early Detection and Management of Pulmonary Arterial Hypertension PDF Print E-mail
Wednesday, 06 March 2013 16:03
The long-term prognosis for patients with pulmonary arterial hypertension (PAH) remains poor, despite advances in treatment options that have been made in the past few decades. Recent evidence suggests that World Health Organization functional class I or II patients have significantly better long-term survival rates than patients in higher functional classes, thus providing a rationale for earlier diagnosis and treatment of PAH. However, early diagnosis is challenging and there is frequently a delay between symptom onset and diagnosis.

Screening programmes play an important role in PAH detection and expert opinion favours echocardiographic screening of asymptomatic patients who may be predisposed to the development of PAH (i.e. those with systemic sclerosis or sickle cell disease), although current guidelines only recommend annual echocardiographic screening in symptomatic patients. This article reviews the currently available screening programmes, including their limitations, and describes alternative screening approaches that may identify more effectively those patients who require right heart catheterisation for a definitive PAH diagnosis.

To read the full article, click on and download from the link provided below.


 
More articles :

» Rituximab for Scleroderma: Does Something Finally Work?

Kevin Deane, MDPosted: 03/10/2010Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle StudyDaoussis D, Liossis SN, Tsamandas AC, et al. Rheumatology (Oxford). 2010;49:271-280BackgroundMultiple drugs have been tried in...

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...

» FDA Approves New Lupus Drug

The FDA has approved (Benlysta) for reducing disease activity in (SLE), making it the first new lupus drug in more than 50 years. Belimumab is a monoclonal antibody targeting the B-lymphocyte stimulator protein, called BLyS. It was co-developed by...

» Aspirin, Simvastatin Not Effective for Pulmonary Arterial Hypertension

Neither aspirin nor simvastatin improved outcomes for patients with in a phase II safety and efficacy trial recently published online in and simultaneously presented at the annual meeting of the .The primary end point of 6-minute walk distance did...

» Understanding Autoimmunity

What is Autoimmunity?One of the functions of the immune system is to protect the body by responding to invading microorganisms, such as viruses or bacteria, by producing antibodies or sensitized (types of white blood cells). Under normal...

» UTHealth Uses $1.9 million Grant To Study Therapy For Autoimmunity

A researcher at (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.The preclinical study, funded with a $1.9 million grant...